MacroGenics

MGNX NASDAQ
16.40
-0.24
-1.44%
交易中 14:05 06/24 EDT
开盘
16.59
昨收
16.64
最高
16.69
最低
16.13
成交量
30.85万
成交均量(3M)
83.00万
52周最高
32.32
52周最低
9.87
换手率
0.63%
市值
8.00亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供MacroGenics MGNX股票价格,MacroGenics股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
展开 >

最近浏览

名称
价格
涨跌幅